PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-201.62%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-201.62%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-128.59%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-127.78%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-127.78%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.70%
Positive OCF growth while AVXL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
37.70%
Positive FCF growth while AVXL is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.48%
Positive long-term OCF/share growth while AVXL is negative. John Neff would see a structural advantage in sustained cash generation.
24.48%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
24.48%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
9.10%
Positive 10Y CAGR while AVXL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
9.10%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
9.10%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
-301.87%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-301.87%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-301.87%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.07%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-11.47%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
6.41%
Debt shrinking faster vs. AVXL's 19.59%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
186.72%
SG&A growth well above AVXL's 47.36%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.